Femtech Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines femtech, meaning digital health apps, wearables, devices, diagnostics and virtual care services for menstrual health, fertility, pregnancy and maternal care, menopause, pelvic health and sexual health. It tests how far rising investment turns into clinically validated products and paid care, and which participants capture value among virtual care companies, device makers, fertility platforms and payers.

Investment is concentrated in care delivery. Midi Health raised USD 100 million in a Series D round in February 2026 for virtual perimenopause and menopause care, at a reported valuation above USD 1 billion, and Pomelo Care raised USD 92 million in a Series C round in January 2026 for virtual prenatal, pregnancy and postpartum care, at a reported valuation of USD 1.7 billion. The conclusion is that investors are backing clinician-led services that payers and employers pay for, ahead of stand-alone apps.

Funding also reaches devices and diagnostics. Materna Medical, May Health, Rejoni and iPremom each raised between about USD 5 million and USD 25 million during 2026 for a pelvic floor device, an ovulation-restoring device, a uterine hydrogel and a first-trimester blood test, and a July 2026 roundup counted 17 femtech rounds with more than USD 120 million disclosed. The conclusion is that the early pipeline is broad, and clearance by regulators is the gate between funding and revenue.

Large groups are now buying in. Ferring Pharmaceuticals has proposed to acquire the fertility biotech company Gameto for up to USD 1.3825 billion including milestone payments, and the deal had not closed when reported at the start of November 2026. The conclusion is that fertility is attracting pharmaceutical acquirers, which brings capital and regulatory experience to the segment.

The brief treats femtech as an accelerating signal with an eight year horizon to 2034. It identifies which applications, regions and companies scale first and what each means for digital health companies, device makers, providers and payers. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Femtech applies digital tools, devices and diagnostics to health needs specific to women, from menstrual cycles and fertility to pregnancy, menopause and pelvic health.

Virtual care companies provide clinician consultations, prescriptions and follow-up through apps. Wearables and home tests track hormones, temperature and other signals, and devices treat conditions such as pelvic floor injury.

Performance depends on the accuracy of predictions, clinical validation and regulatory clearance, and on keeping user data private.

Uses are cycle tracking, fertility treatment and monitoring, prenatal and postpartum care, menopause care, pelvic health and sexual health diagnostics.

The limits are regulatory clearance for devices, data privacy, reimbursement gaps and consolidation of early companies. The period turns on payer coverage of validated products.

The femtech market, covering digital health apps, wearables, devices, diagnostics and virtual care services for menstrual health, fertility, pregnancy and maternal care, menopause, pelvic health and sexual health, and excluding hospital obstetric services and prescription drugs, is valued at USD 25–35 billion in 2026 and is projected to reach USD 57.61–80.66 billion by 2034, at a CAGR of 11%.

The 2026 base rests on subscription apps, virtual care services, devices and diagnostics sold directly and through employers and payers. Growth then follows coverage of virtual menopause, fertility and maternal care and the clearance of home tests and devices.

The forecast is sensitive to payer coverage, regulatory clearance and data privacy rules. Regionally, North America holds the largest base through virtual care companies and employer programmes, Europe is led by app and device companies, and Asia-Pacific grows from a smaller base.

The base case assumes payer and employer coverage of virtual menopause, fertility and maternal care widens by 2028 and validated home tests and devices reach mainstream use by 2030. An accelerated case assumes quick clearances and broad coverage, bringing the inflection to 2028 and lifting the 2034 value to the top of the range. A delayed case assumes slow clearances and tighter privacy rules, holding growth at the bottom of the range.

Growth drivers

• Venture and growth funding.
• Demand for menopause and fertility care.
• Virtual care for pregnancy and postpartum.
• Home hormone and microbiome testing.

Enablers

• Employer and payer programmes.
• Wearable platforms.
• Clinical research partnerships.
• Government research funding.

Restraints and barriers

• Regulatory clearance for devices.
• Data privacy concerns.
• Reimbursement gaps.
• Consolidation of early companies.

The direction of femtech is set by investment in menopause, fertility and maternal health, coverage by employers and health plans, wearables and home testing, policy attention to women health research, and data privacy and regulatory clearance.

The key participants in femtech include Flo Health, Inc., Maven Clinic Co., Midi Health, Inc., Pomelo Care, Inc., LetsGetChecked Limited, Natural Cycles Nordic AB, BioWink GmbH, Oura Health Oy, Kindbody, Inc., Progyny, Inc., Carrot Fertility, Inc., Gameto, Inc., ReproNovo SA, Conceivable Life Sciences, Inc., Overture Life, Inc., Willow Innovations, Inc., Hologic, Inc., Ferring Holding SA, Diana Health, Inc., Rejoni, Inc., Materna Medical, May Health, iPremom, Juno Bio, Stripes, Khosla Ventures, Goodwater Capital, Amadeus Capital Partners, Asabys Partners, HealthQuest Capital, InnovaHealth Partners, University of Bologna, University of California San Diego Health, American College of Obstetricians and Gynecologists, American Heart Association, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, The Menopause Society, U.S. Food and Drug Administration, National Institutes of Health, U.S. Department of Health and Human Services and World Health Organization.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as coverage widens.

Flo Health, Natural Cycles and BioWink lead among apps, Maven Clinic, Midi Health and Pomelo Care lead among virtual care companies, and Kindbody, Progyny and Carrot Fertility lead among fertility platforms. Competitive intensity is high in apps and rising in virtual care.

Where value migrates.

In 2026 value sits with virtual care and fertility platforms, because payers and employers already pay for services delivered by clinicians. By 2030 it moves toward companies with clinically validated products, because coverage follows evidence. By 2034 it settles in integrated platforms that link data, testing, devices and care across life stages. Margins hold for companies with payer contracts and cleared products and narrow for stand-alone apps competing on subscriptions.

The signals converge on funding and consolidation. Large rounds for virtual care, a broad early pipeline and a proposed acquisition of up to USD 1.3825 billion support growth, while clearance, privacy and reimbursement limit the pace.

Structural limits show where progress could slow: regulatory clearance for devices, data privacy concerns, reimbursement gaps and consolidation of early companies. The brief therefore tracks four indicators: patients served, payer contracts, clearances and funding rounds.

Virtual care first, then home testing and diagnostics, then cleared devices are the expected order of adoption.